SPR Therapeutics out of Cleveland, Ohio received FDA clearance for its SPRINT Peripheral Nerve Stimulation (PNS) System, the first minimally invasive and completely removable peripheral nerve stimulator indicated for chronic and acute pain.
The device connects to a coiled electrode lead that is implanted percutaneously and is held in place by a patch for up to thirty days. The neurostimulator itself is about the size of a bandage, and it sends electrical signals toward a target nerve that can be as distant as three centimeters away from the lead tip.
The company hopes their device will provide some patients a viable option over drugs, and perhaps even put a dent into the overall usage of opiods in our society.
From SPR Therapeutics:
A physician can place the system during a short outpatient procedure without surgery or anesthesia. Because SPRINT is minimally invasive and completely reversible, physicians may use it earlier in a patient’s treatment process in an effort to reduce or eliminate the need for opiates and to avoid costly alternatives in managing acute and chronic pain.
Multiple clinical trials evaluating SPRINT have demonstrated its ability to reduce pain and improve quality of life. In one study funded by the National Institutes of Health, use of SPR’s system was associated with a 72 percent reduction in average pain. SPR will continue to sponsor clinical trials to further expand into specific indications.
The SPRINT system has been approved in Europe for over three years.
Product page: SPRINT PNS System…
Source: SPR Therapeutics